KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Tax Provisions: 2023-2024

Historic Tax Provisions for Recursion Pharmaceuticals (RXRX) over the last 2 years, with Dec 2024 value amounting to -$1.1 million.

  • Recursion Pharmaceuticals' Tax Provisions fell 98.20% to $3,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $19,000, marking a year-over-year increase of 100.37%. This contributed to the annual value of -$1.1 million for FY2024, which is 72.26% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Tax Provisions of -$1.1 million as of FY2024, which was up 72.26% from -$4.1 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Tax Provisions ranged from a high of -$1.1 million in FY2024 and a low of -$4.1 million during FY2023.
  • Moreover, its 2-year median value for Tax Provisions was -$2.6 million (2023), whereas its average is -$2.6 million.
  • Data for Recursion Pharmaceuticals' Tax Provisions shows a peak YoY surged of 72.26% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Recursion Pharmaceuticals' Tax Provisions stood at -$4.1 million in 2023, then soared by 72.26% to -$1.1 million in 2024.